As a world-renowned biotech company that produces bioactive materials, Bloomage Biotech (688363) stays committed to engendering good health and happiness in the lives of its customers through its diversified range of products.
Bloomage Biotechnology Corporation Limited. is a company integrating R&D, production and sales of hyaluronic acid. Our microbial fermentation technology for hyaluronic acid production is in a dominant position. Relying on the bio-fermentation technology platform and industrialization advantages, the company has developed a series of BIOACTIVE products with hyaluronic acid as the core. We’ve estabished nearly 200 specifications of hyaluronic acid, which are widely used in pharmaceutical, medical device, cosmetics and functional foods industry. We also offer other bioactive products, such as Bioecto™ Ectoine, Bioyouth™-EGT Ergothioneine Complex, Hyafactor™ – PGA Sodium Polyglutamate, Hyafactor™ – SG Sclerotium Gum Hydrogel, Bioyouth™ – Natto Natto Extract, Bioyouth™ – Brice Brown Rice Ferment Filtrate., etc..
Bloomage Biotech believes a company’s vitality comes from its continuous innovation and profitability, and therefore strives to realize its medium and long-term strategic goals by ensuring its presence in the industrial, supply and value chain sectors/domain. In addition, the company seeks to stay ahead and maintain its ability to set the standard within the industry using its microbial fermentation and cross-linking technical platforms. With its strong market presence, Bloomage Biotech aims to become a key link in building control intermediate links in the supply chain, coupled with its sharp competitiveness obtained through technological expertise, products and market presence, the company aspires to be the core hub for the optimal allocation of resources in the value chain.
Science, technology and innovation not only guarantee Bloomage Biotech’s sound growth, but also fuel its rapid business growth. Over the past 20 years, Bloomage Biotech has endeavored to build a strong brand image continually enhancing its innovation through its deployment of technology. On November 6, 2019, Bloomage Biotech embarked on a new chapter of innovation and development when the company officially went public on the sci-tech innovation board of the Shanghai Stock Exchange!
Going forward, Bloomage Biotech will stay committed to sharpening its core competitiveness in technology, products and brand, by developing more high-quality bioactive raw materials and related end products, and playing a bigger role in supporting/engendering generally healthier, happier lives for people/it’s customers/clients. Bloomage Biotech aims to become a company that Chinese take pride in, a company that is well-respected nationally/world-wide for its expertise and value.